{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:27:13Z","timestamp":1765268833334,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.amepre.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T02:12:59Z","timestamp":1657505579000},"page":"1062-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable"],"prefix":"10.1016","volume":"63","author":[{"given":"Eli Y.","family":"Adashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5125-2991","authenticated-orcid":false,"given":"Philip A.","family":"Gruppuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.amepre.2022.06.009_bib0001","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amepre.2022.06.009_bib0002","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines \u2013 fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"6553","key":"10.1016\/j.amepre.2022.06.009_bib0003","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.abg9857","article-title":"Scent of a vaccine","volume":"373","author":"Lund","year":"2021","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.amepre.2022.06.009_bib0004","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.amepre.2022.06.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103841","article-title":"Intranasal COVID-19 vaccines: from bench to bed","volume":"76","author":"Alu","year":"2022","journal-title":"EBiomedicine"},{"key":"10.1016\/j.amepre.2022.06.009_bib0006","unstructured":"ClinicalTrials.gov, NIH U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/home. Accessed May 13, 2022."},{"issue":"4","key":"10.1016\/j.amepre.2022.06.009_bib0007","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.amepre.2022.06.009_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1472-6750-10-77","article-title":"Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis","volume":"10","author":"Lorenzi","year":"2010","journal-title":"BMC Biotechnol"},{"issue":"7851","key":"10.1016\/j.amepre.2022.06.009_bib0009","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/d41586-021-00728-2","article-title":"Five reasons why COVID herd immunity is probably impossible","volume":"591","author":"Aschwanden","year":"2021","journal-title":"Nature"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379722003373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379722003373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:07:59Z","timestamp":1760083679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379722003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0749379722003373"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2022.06.009","relation":{},"ISSN":["0749-3797"],"issn-type":[{"type":"print","value":"0749-3797"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}